Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
246 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Rank Status Study
21 Temporarily not available Pulmonary Vein Isolation Outcomes With Fish Oils
Condition: Atrial Fibrillation
Intervention: Drug: Lovaza (Fish Oils)
22 Temporarily not available An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient
Condition: Mucopolysaccharidosis Type 7
Intervention: Drug: UX003
23 Temporarily not available 99m-Technetium- Glucosamine in Arthritis
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis
Intervention: Device: Technetium labelled glucosamine
24 No longer available Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
Conditions: Metastatic Liver Cancer;   Ocular Melanoma;   Cutaneous Melanoma
Interventions: Drug: Melphalan;   Device: Percutaneous Hepatic Perfusion
25 No longer available An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
Condition: HIV Infection
Intervention: Drug: Efavirenz
26 Available Treatment Use of Domperidone for Gastroparesis
Conditions: Gastroesophageal Reflux Disease;   GERD;   Gastroparesis
Intervention: Drug: Domperidone
27 Available Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Condition: Patient 0001-000412 Under Study P05538
Intervention: Drug: ficlatuzumab
28 No longer available Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: nilotinib
29 Approved for marketing Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Condition: Cancer
Intervention: Drug: Denileukin diftitox (ONTAK)
30 No longer available Emergency/Compassionate Use - AMPLATZER Duct Occluder
Conditions: Patent;   Ductus;   Arteriosus
Intervention: Device: Device closure with the AMPLATZER Duct Occluder
31 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Childhood Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
32 No longer available Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil (Revatio) 20 mg TID
33 Available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
34 Approved for marketing Korean Early Access Program
Condition: Leukemia
Intervention: Drug: Dasatinib
35 No longer available Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: Glivec
36 Approved for marketing VX-770 Expanded Access Program
Condition: Cystic Fibrosis
Intervention: Drug: VX-770
37 Approved for marketing The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
38 Available International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Conditions: Metastatic Gastric Cancer;   Metastatic Adenocarcinoma of the Gastroesophageal Junction
Intervention: Biological: Ramucirumab
39 Approved for marketing Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
Condition: HIV Infections
Intervention: Drug: raltegravir
40 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years